Evidence map›Paper›PMID 31858386›Full record

ArticleJournal of bioethical inquiry2020

Developing and Implementing new TB Technologies: Key Informants' Perspectives on the Ethical Challenges.

Renaud F Boulanger, Ana Komparic, Angus Dawson, Ross E G Upshur, Diego S Silva

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bioethical inquiry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Lead Essay: Money, Equity and Access to Medicines.Journal of bioethical inquiry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Renaud F BoulangerCentre for Applied Ethics, McGill University Health Centre, 2155 Guy Street, 2nd floor, Montreal, Quebec, H3H 2R9, Canada.
Ana KomparicLeslie Dan Faculty of Pharmacy & Joint Centre for Bioethics, University of Toronto, 144 College Street, Toronto, Ontario, M5S 3M2, Canada.
Angus DawsonSydney Health Ethics & Marie Bashir Institute for Infectious Diseases and Biosecurity, Level 1, Medical Foundation Building, The University of Sydney, Sydney, NSW, 2006, Australia.
Ross E G UpshurDalla Lana School of Public Health & Joint Centre for Bioethics, University of Toronto, 155 College Street, Toronto, ON, M5T 1P8, Canada.
Diego S SilvaSydney Health Ethics & Marie Bashir Institute for Infectious Diseases and Biosecurity, Level 1, Medical Foundation Building, The University of Sydney, Sydney, NSW, 2006, Australia. diego.silva@sydney.edu.au.
McGill University Health Centre · CAPublic Health Ontario · CATaronga Conservation Society Australia · AUUniversity of Sydney · AUUniversity of Toronto · CA

Funding

CIHR 326537
6 · The paper itself

Abstract

objectiveTo identify the ethical challenges associated with the development and implementation of new tuberculosis (TB) drugs and diagnostics.

methodsTwenty-three semi-structured qualitative interviews conducted between December 2015 and September 2016 with programme administrators, healthcare workers, advocates, policymakers, and funders based in the Americas, Europe, and Africa. Interviews were analysed using thematic analysis.

resultsDivergent interests and responsibilities, coupled with power imbalances, are a primary source of ethical challenges; the uncertain risk profiles of new drugs present an additional one. Although this challenge can be partially mitigated through stringent pharmacovigilance, respondents highlighted that high-burden countries tend to lack the resources to facilitate safe implementation. Increased advocacy and community engagement are considered an ethical imperative for future TB development and implementation.

conclusionsThis project helps identify some of the ethical challenges of new TB technologies. It demonstrates that investigating ethical challenges through qualitative research is one way to apprehend the difficulty of implementing new TB technologies. Addressing this difficulty will require that those in positions of power reconsider their interests in relation to disempowered communities. POLICY IMPLICATIONS: Efforts to build consensus regarding what values should underpin the global governance of TB research, prevention, and care are essential to facilitate the ethical implementation of new TB technologies.

Indexed as

Biomedical TechnologyDeveloped CountriesDeveloping CountriesHealth Services Needs and DemandHumansQualitative ResearchTuberculosisDrugs and diagnosticsEthicsJusticeQualitativeTuberculosis

Identifiers

PMID31858386
OpenAlexW2995927015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.